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Neuromuscular imaging in inherited muscle
diseases
Abstract Driven by increasing num-
bers of newly identiﬁed genetic
defects and new insights into the
ﬁeld of inherited muscle diseases,
neuromuscular imaging in general
and magnetic resonance imaging
(MRI) in particular are increas-
ingly being used to characterise
the severity and pattern of muscle
involvement. Although muscle
biopsy is still the gold standard for
the establishment of the deﬁnitive
diagnosis, muscular imaging is an
important diagnostic tool for the
detection and quantiﬁcation of
dystrophic changes during the
clinical workup of patients with
hereditary muscle diseases. MRI is
frequently used to describe muscle
involvement patterns, which aids
in narrowing of the differential
diagnosis and distinguishing
between dystrophic and non-
dystrophic diseases. Recent work
has demonstrated the usefulness of
muscle imaging for the detection
of speciﬁc congenital myopathies,
mainly for the identiﬁcation of the
underlying genetic defect in core
and centronuclear myopathies.
Muscle imaging demonstrates
characteristic patterns, which can
be helpful for the differentiation of
individual limb girdle muscular
dystrophies. The aim of this
review is to give a comprehensive
overview of current methods and
applications as well as future per-
spectives in the ﬁeld of neuro-
muscular imaging in inherited
muscle diseases. We also provide
diagnostic algorithms that might
guide us through the differential
diagnosis in hereditary myopathies.
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Introduction
During the past few years, substantial progress in the
genetic diagnosis of inherited neuromuscular diseases has
led to new insights into the pathological understanding of
the disease. This in turn has led to the identiﬁcation of
numerous new genetic abnormalities associated with
dystrophic or non-dystrophic disease of the striated
muscles. In addition to the neurological examination and
neurophysiological assessment, neuromuscular imaging is
increasingly becoming an important diagnostic tool in
detecting muscular involvement as well as describing the
degree and pattern of involvement. Neuromuscular imag-
ing can therefore be helpful in supporting the clinical
diagnosis, limiting the complex range of differential
diagnoses and guiding interventional diagnostic proce-
dures such as muscle biopsy. Since the introduction of
ultrasound in the early 1980s as a diagnostic tool in
neuromuscular diseases, the dynamic ﬁeld of neuromus-
cular imaging techniques has become more fascinating but
also complex.
Recent reviews have given a ﬁrst overview concerning
imaging techniques and clinical applications in patients
with inherited, metabolic and inﬂammatory muscle dis-
eases [1–4]. Given the dynamic development in this ﬁeld
of research, the aim of this review is to give a
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comprehensive overview of the available imaging techni-
ques and present an update of clinical neuromuscular
imaging applications in patients with inherited muscle
diseases. Furthermore, we would like to try to give some
guidelines about how and to what extent neuromuscular
magnetic resonance imaging (MRI) can lead us in the
right direction in terms of narrowing the differential
diagnosis and making the right diagnosis prior to interven-
tional diagnostic procedures such as muscle biopsy.
Imaging techniques
Before discussing the diagnostic value of different imag-
ing techniques in the detection of muscle abnormalities in
patients with inherited muscle disorders, we have to be
aware that striated muscle is a dynamic tissue that is
inﬂuenced by many factors such as exercise, age and
gender [5]. These physiological changes can be observed
across all imaging techniques and have to be distinguished
from pathological changes.
Age is one of the most important factors inﬂuencing
muscle tissue appearance [6]. During childhood, muscle
thickness increases rapidly and is not relevantly inﬂuenced
by gender. After puberty, the gender-speciﬁc muscle
development starts (men develop thicker muscles after
puberty than women), reaching a peak of muscle volume
between 25 and 40 years of age, followed by a subsequent
decrease in muscle volume. The inﬂuence of age and
gender is, however, not constant and differs slightly for
each muscle group [6–9].
Ultrasound
Ultrasound (US) is a well-established and validated
diagnostic imaging method in the evaluation of patients
with suspected muscle disorders [10]. It is a relatively
cheap and easily applicable method, allowing the visual-
isation of striated muscle with a high temporal resolution
(>0.1 mm). The major advantage of US is the lack of any
radiation exposure, which makes it the perfect imaging
method for the evaluation of children. It even allows
dynamic imaging of contracting muscles and can visual-
ise pathological muscle activity such as fasciculation
[11–13].
A major drawback of US is that its application is
limited to superﬁcial muscle groups. Sound wave reﬂec-
tion and absorption lead to difﬁculties in displaying the
deeper structures. This effect becomes even more pro-
nounced when multiple muscle groups overlap. Another
disadvantage is the relatively low inter-observer agree-
ment and intra-observer agreement (depending on the
level of experience), which makes a strictly standardised
examination (e.g. according to certain anatomical land-
marks) crucial [2, 14]. However, ultrasound is a reliable
method concerning the measurement of muscle thickness
and muscle echo intensity. In addition, by measuring
muscle echo intensity it is possible to further characterise
age-related or pathological changes of the striated muscles
with special regard to dystrophic changes in terms of fatty
degeneration and replacement of muscle by connective
tissue (Fig. 1). In order to quantify the degree of fat
deposition there are several ratings scales available (e.g.
the Heckmatt score) as well as computed-assisted quanti-
ﬁcation methods of muscle echo intensity [15–19].
Ultrasound applications are widely and routinely used in
neuromuscular disorders in terms of assessment of changes
in muscle morphology (atrophy, hypertrophy, changes in
muscle architecture). In particular it is a useful screening tool
during the initial diagnostic phase, especially in children.
Depending on the disease entity, the sensitivity of detecting
dystrophic changes ranges from 25% in non-dystrophic
myopathies up to 100% in dystrophic myopathies (Duch-
enne muscular dystrophy) [10, 19, 20]. The detection of
pathological changes can be helpful in guiding muscle
biopsy, and the description of the muscle involvement
pattern might help in the differential diagnosis [10, 21].
Computed tomography
Computed tomography (CT) has been widely used in the
past in order to evaluate the presence and extent of change
in the striated muscles in patients with hereditary neuro-
muscular disorders [2, 22–24]. CT is a fast imaging
method that is easy to apply and allows a good and
standardised assessment of the aspect and shape of the
muscles as well as dystrophic changes (in particular fatty
degeneration). CT is also relatively operator-independent
and allows the evaluation of deeper muscle groups, and
newer CT methods using multi-detector rows provide
improved imaging possibilities in terms of spatial reso-
lution and multi-planar reconstructions. However, CT has
substantial drawbacks leading to an almost complete
replacement of this imaging technique by US and MRI.
One of the most relevant disadvantages of CT compared
with US and MRI is the relatively high radiation dose,
which makes the application obsolete, especially in
children. Because of the high radiation dose, whole-body
applications in order to describe the pattern of muscle
involvement are not desired. Another drawback of CT is
the limited soft tissue contrast, which substantially impairs
the sensitivity in the detection of inﬂammatory changes
(e.g. oedema) that can precede muscle dystrophy.
Magnetic resonance imaging
MRI is increasingly being used in the evaluation of
patients with suspected or proven inherited or metabolic
neuromuscular disorders. MRI provides a high soft tissue
contrast allowing excellent assessment of striated muscles
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concerning shape, volume (hypotrophy, hypertrophy) and
tissue architecture [1, 2]. Because of the lack of ionising
radiation, MRI has become a valuable imaging method in
children, although sometimes sedation might be necessary.
Basically, MRI is performed as a multi-sequence imaging
protocol including T1-weighted (T1W) and T2-weighted
(T2W) (turbo) spin echo as well as fat-suppressed (short
tau inversion recovery or spectral fat suppression techni-
ques) T2-weighted sequences (T2WFS). The image
acquisition is performed in the axial plane with a slice
thickness of 5-7 mm. If necessary, additional images in
other anatomical planes (coronal, sagittal) can be easily
acquired.
Dystrophic changes such as fatty degeneration can be
easily and sensitively detected using the T1W and T2W
sequences. In addition, inﬂammatory changes such as
muscle oedema can be depicted on the T2WFS sequences
(Fig. 2). It has been conclusively shown that MRI has a
higher sensitivity in the detection of dystrophic changes
compared with CT [22, 23]. MRI can be performed and
rated in a standardised manner suggesting a good inter-
rater agreement and intra-rater (during follow-up) agree-
ment. The degree of muscular dystrophy in inherited
muscle diseases is rated according to rating scales [25–
27]. Most of the established rating scales are based on the
amount of fatty degeneration ranging from normal
appearance to complete fatty degeneration (Table 1). The
evaluation of the muscle MRI using standardised rating
scales allows a fast and reproducible assessment of the
degree of involvement of each muscle. Initially, muscle
MRI protocols were developed to evaluate certain ana-
tomical areas such as the lower extremities and pelvis.
More recent whole-body imaging protocols have been
established allowing the evaluation of almost all relevant
striated muscle groups. Pattern recognition of muscle
involvement is sometimes helpful in narrowing the differ-
ential diagnosis and leading to the most probable
diagnosis before muscle biopsy. Because of the lack of
any radiation exposure, muscle MRI has become an
important diagnostic technique for the evaluation of
children [3]. In addition, whole-body MR imaging
protocols allow evaluation of tissues and organs beyond
the striated muscle such as the parenchymatous organs in
the abdomen, the oesophagus and heart, all of which can
be affected in patients with inherited neuromuscular
diseases [28, 29] (Fig. 3).
Using T2WFS sequences, MRI can sensitively detect
discrete toxic, metabolic and inﬂammatory changes that
are reﬂected by muscle oedema, which normally precedes
dystrophic changes in terms of fatty degeneration. There-
fore, MRI is able to detect ongoing disease activity in the
muscle tissue and can be helpful in guiding muscle biopsy
(Fig. 2).
The diagnostic value of contrast-enhanced (CE) MR
imaging protocols has not been investigated so far. Late
contrast enhancement may be a valuable option for the
assessment of connective tissue that replaces normal
muscle tissue in degenerative myopathies. However, this
assessment is associated with a substantial increase in
examination time. Therefore, CE MR imaging should not
been performed on a regular basis. Recently performed
animal studies with more speciﬁc contrast agents entering
affected muscle tissue have shown that CE MRI might be
helpful in distinguishing normal non-affected muscles
from damaged muscles and further describe the extension
and mechanism of muscular damage in dystrophic
disorders [30, 31]. However, more prospective studies
are necessary before the clinical application of such
imaging protocols in humans during the diagnostic
workup.
Quantitative MRI methods such as T2 relaxation time
measurements, muscle fat quantiﬁcation using the 3-point
Fig. 1 Ultrasound images of
the quadriceps muscle in normal
control (a) and a patient with
Duchenne muscular dystrophy
(b). In the healthy subject (a),
muscle appears largely black
with few perimysial septa. Note
the increased homogeneous ﬁne
granular echogenicity of muscle
due to increased replacement of
normal muscle by connective and
fatty tissue in the patient with
muscular dystrophy (b)
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Dixon technique, magnetic resonance spectroscopy and
perfusion imaging might be helpful to further analyse the
degree of pathological changes in the striated muscles
[32–34]. In particular blood ﬂow measurements in the
striated muscle based on either dynamic contrast-enhanced
T1-weighted MRI, arterial spin labelling or blood oxygen-
dependent MRI can be helpful to distinguish between
inﬂammatory (increase of microvascular perfusion) and
Table 1 Summary of the well-established rating scales on MRI concerning the visual rating of dystrophic change of striated muscle tissue
Grade Mercuri et al. 2002 [25] Kornblum et al. 2006 [27] Fischer et a. 2008 [26]
0 Normal appearance Normal appearance
1 Normal appearance Discrete moth-eaten
appearance with sporadic T1
hyperintense areas
Mild: traces of increased signal intensity
on the T1-weighted MR sequences
2 Mild involvement: Early moth-eaten appearance
with scattered small areas of increased signal or
with numerous discrete areas of increased signal
with beginning conﬂuence, comprising less than
30% of the volume of the individual muscle
a. Moderate moth-eaten
appearance with numerous
scattered T1 hyperintense
areas
Moderate: increased T1-weighted signal
intensity with beginning conﬂuence in
less than 50% of the muscle
b. Late moth-eaten appearance
with numerous conﬂuent T1
hyper-intense areas
3 Moderate involvement: Late moth-eaten
appearance with numerous discrete areas of
increased signal with beginning conﬂuence,
comprising 30-60% of the volume of the
individual muscle
Complete fatty degeneration,
replacement of muscle by
connective tissue and fat
Severe: increased T1-weighted signal
intensity with beginning conﬂuence in
more than 50% of the muscle
4 Severe involvement: Washed-out appearance, fuzzy
appearance due to conﬂuent areas of increased
signal or an end-stage appearance, with muscle
replaced by increased density connective tissue
and fat, and only a rim of fascia and
neurovascular structures distinguishable
End-stage appearance, entire muscle
replaced by increased density of
connective tissue and fat
Fig. 2 Transverse T1-weighted (upper row) and spectral fat-suppressed
T2-weighted MR image (bottom row) of the thighs of a 48-year-old
woman presenting with myotonic dystrophy type 1. Note the
different degrees of fatty degeneration within the gastrocnemius
muscle. The medial head shows an end-stage fatty degeneration
(grade 4 according to the Mercuri and Fischer scale, grade 3
according to the Kornblum scale, Table 1). The muscle tissue is
completely replaced by fat. The lateral head shows a moth-eaten
appearance with scattered small areas of increased signal (fatty
degeneration grade 2 according to the rating scales established by
Mercuri et al., Kornblum et al. and Fischer et al., Table 1). The fat-
suppressed T2-weighted image shows a high signal in the medial
head of the gastrocnemius muscle indicating oedema because of
inﬂammatory changes before and during the degenerative disease
stages
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degenerative/dystrophic changes [4, 35]. However, there
have been only a limited number of studies with low
numbers of included subjects available up to now. There-
fore, these techniques remain experimental for this
purpose and should not be considered a standard imaging
tool in the clinical routine setting.
Muscle imaging in muscular dystrophies
Muscular dystrophies are characterised by permanent and
progressive muscle weakness. Clinical, pathological and
genetic classiﬁcations are overlapping and heterogeneous.
However, the most common separation is made according
to the age of onset and the pattern of involved (e.g. facial,
proximal, distal) muscles.
In dystrophinopathies, onset of (proximal) weakness is
in the ﬁrst decade of life. Limb-girdle muscular dystro-
phies (LGMD) are a group of autosomal dominantly or
recessively inherited muscular dystrophies that also
present with primary proximal (limb-girdle) muscle
weakness. However, most LGMDs start in the second
decade of life. Myoﬁbrillar myopathies (MFM) are a
group of adult-onset myopathies, often beginning in the
third or fourth decades of life. In contrast to LGMD,
muscle weakness often starts in the distal muscles. Other
dystrophies such as myotonic dystrophy or FSHD have
often a characteristic pattern of clinical weakness but can
start at any age.
Early onset (proximal) LGMD and dystrophinopathies
In western and central Europe, LGMD2I, LGMD2A and
LGMD2B are probably the most common LGMD forms.
A muscle biopsy including protein expression analysis is
usually necessary to distinguish among LGMD subtypes
[36, 37]. LGMDs also present with different patterns of
muscle involvement on imaging that might help in the
genetic diagnosis. An illustration of different muscle
imaging ﬁndings in LGMD patients is provided in
Fig. 4.
FKRP-related myopathies (LGMD2I)
A few years ago, a novel gene encoding a putative
glycosyltransferase, fukutin-related protein (FKRP), was
found to be responsible for both a novel form of
congenital muscular dystrophy (MDC1C) and for a form
of limb girdle muscular dystrophy (LGMD2I) [38, 39].
Recently, we performed a systematic clinical and muscular
MRI assessment in several LGMD2I patients and com-
pared these ﬁndings with those of other patients with
genetically conﬁrmed diagnosis of other forms of autoso-
mal recessive LGMDs or dystrophinopathies [40].
All LGMD2I patients had a characteristic muscular
phenotype on MRI of the lower extremities that demon-
strated marked signal changes in the adductor muscles, the
posterior thigh and posterior calf muscles. Furthermore,
data of patients with different clinical disease severity
pointed towards a speciﬁc temporal pattern. At the pelvic
level, the gluteus maximus was involved earlier and more
severely than the gluteus medius. At the thigh level the
earliest and most severe changes were observed in the
adductor (magnus) muscles and the biceps femoris. With
further progression degenerative changes were noticed in
the remaining hamstring muscles and to a lesser degree in
the vastus lateralis and vastus intermedius muscles.
Involvement of the vastus medialis and rectus femoris
was only observed in the patient with advanced disease,
while the sartorius and gracilis muscles were relatively
spared. In the lower legs relatively diffuse changes in the
medial head of the gastrocnemius and the soleus muscle
were observed early in the disease, while involvement of
the anterior compartment muscles was only observed in
later stages of the disease. The tibialis anterior muscle was
usually spared and often hypertrophied.
Calpainopathies (LGMD2A)
Compared with LGMD2I, in patients with LGMD2A,
caused by mutation in the calpain-3 gene, we observed a
very similar and consistent clinical and muscle imaging
phenotype. As in LGMD2I, muscle MRI images have
conﬁrmed the clinical observation that in LGMD2A there
Fig. 3 Transverse spectral fat-suppressed T2-weighted images
obtained from two patients presenting with a myotonic dystrophy
type 1 (A: 37-year-old woman; B: 16-year-old boy). The images
were obtained during a multi-sequence whole-body muscle MRI
protocol. In both patients, dilatation of the oesophagus in the
proximal segment with the air-ﬂuid level could be diagnosed, which
was clinically reﬂected by dysphagia
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is early and predominant involvement of posterior
compartment muscles such as the gluteus maximus in
the pelvis, semimembranosus, biceps femoris and adduc-
tor muscles in the thigh, with relative sparing of the vastus
lateralis, sartorius and gracilis. These ﬁndings were also
later conﬁrmed by others [41]. Contrary to LGMD2I,
there are, however, some important differences: the vastus
lateralis is spared more in LGMD2A compared with
LGMD2I; the medial gastrocnemius and soleus muscles
are much more selectively involved compared with the
diffuse afﬂiction seen in LGMD2I, and hypertrophy of the
tibialis anterior muscle is only rarely present in LGMD2A.
Dysferlinopathies (LGMD2B)
Dysferlinopathies, which are genetically characterised by
mutations in the dysferlin gene lead to LGMD 2B, distal
Miyoshi myopathies and a form of distal anterior compart-
ment myopathy [42, 43]. On MRI, symptomatic patients
with dysferlinopathies present with severe dystrophic
changes in the anterior and posterior compartments of
the thighs with a characteristic sparing of the gracilis and
sartorius muscles. In the lower legs, dysferlinopathies
predominantly affect the posterior compartment with a
relative sparing of the medial head of the gastrocnemius
muscle [44–46]. This distinct pattern is different from
muscle involvement in LGMD2I and LGMD2A patients
in which dystrophic changes in the posterior thigh and
posterior calf muscle can frequently be observed [40].
Dystrophinopathies (DMD/ BMD) and sarcoglycanopathies
(LGMD2C, D, E and F)
While sarcoglycan deﬁciencies (LGMD2C, D, E and F)
are relatively rare, dystrophinopathies [type Duchenne
(DMD) and type Becker (BMD)] are the most common
Fig. 4 Flowchart showing the approach to LGMD. Most LGMD
patients have greater afﬂiction of the posterior rather than the
anterior thigh compartment muscles. On the other hand, patients with
dystrophinopathy and sarcoglycanopathy often have signiﬁcant
afﬂiction of the quadriceps muscle. Dystrophinopathy often presents
with early and marked changes in the gastrocnemii muscles, while
patients with sarcoglycanopathy show no afﬂiction of these
muscles. Patients with dysferlinopathy most often show
posterior thigh and posterior lower leg involvement with sparing
of the sartorius, gracilis and biceps femoris. However, muscle
affection can be variable, but clinically calf atrophy and absence
of scapular winging are commonly present. Calpain-3 and FKRP
patients present with predominant posterior thigh and posterior
lower leg involvement. Calpain-3 patients usually show marked
involvement of the soleus and medial gastrocnemius muscles.
Furthermore, calf atrophy and scapular winging are usually
observed. Conversely, FKRP patients have a more diffuse
involvement of the posterior lower leg muscles, while the tibial
anterior muscle is often spared or even hypertrophied
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muscular dystrophies worldwide. Therefore, late onset
BMD patients or sporadic symptomatic female carriers of
DMD often enter the differential diagnosis in sporadic
LGMD patients. Furthermore, recently published studies
emphasised an overlap between LGMD2I and the group
of dystrophinopathies mainly as both often have calf or
generalised muscular hypertrophy, and respiratory and
cardiac involvement [38, 39]. However, on muscle
imaging all our patients with BMD and alpha-sarcogly-
canopathy showed pronounced signal changes in the
anterior rather than the posterior thigh muscles (as present
in LGMD2I patients). In accordance with our results, a
predominant afﬂiction of the anterior thigh compartment
has been observed in dystrophinopathy and LGMD2D
[47–49]. Thus, the relation between knee extensor and
ﬂexor involvement might be useful in distinguishing
dystrophinopathies and sarcoglycan deﬁciencies from
LGMD2I on muscular MRI. Finally, alpha-sarcoglycan-
opathy can be differentiated from BMD patients by the
greater extent of upper limb involvement [47] and by the
different pattern in the lower limbs on muscular MRI [50].
Late onset (distal) myoﬁbrillar myopathies
MFMs are histopathologically characterised by aberrant
desmin aggregation and ultrastructurally by myoﬁbrillar
degeneration, which led to the introduction of the term
`myoﬁbrillar myopathy’ (MFM). Mutations in the human
desmin gene (DES) were ﬁrst shown to be associated with
MFM; another form is associated with mutations in the
gene encoding αB-crystallin (CRYAB). More recently,
mutations in the human Z-disc proteins myotilin (MYOT),
ZASP (LDB3) and ﬁlamin C (FLNC) have also been
shown to cause MFM [51]. Practically, a deﬁnitive
determination of the MFM subtype can only be estab-
lished by direct gene sequencing. However, muscle
imaging in combination with clinical information is very
helpful for separation of distinct MFM subtypes and in
scheduling of genetic analysis.
Recently, we performed muscle imaging in 46 MFM
patients (19 desminopathy, 12 myotilinopathy, 11 ﬁlamin-
opathy, 1 αB-crystallinopathy and 3 ZASPopathy
patients) and observed two major characteristic patterns
of muscle involvement [26]. In desminopathy patients, at
the thigh the semitendinosus was the most affected
muscle, being more affected than the biceps femoris and
semimembranosus muscles. Furthermore, the sartorius and
gracilis muscles were often involved earlier and more
severely than other thigh muscles. At the lower legs,
peroneal muscles were more involved than the tibialis
anterior muscle or at least equally as involved. Muscle
imaging ﬁndings in a patient with a R120G αBC mutation
were very similar to those in desminopathy patients. The
most frequently involved muscles were the gluteus
maximus, semitendinosus, sartorius, gracilis and the
peroneal muscles.
Highly contrarily, all other MFM patients (caused by
mutations of the Z-disc protein-encoding genes myoti-
lin, ﬁlamin c and ZASP) showed an opposite posterior
thigh afﬂiction with more involvement of the biceps
femoris, semimembranosus and the adductor magnus
than the semitendinosus muscle. In ﬁlaminopathy, the
gracilis and sartorius muscles were often relatively
equally spared, while in myotilinopathy the sartorius
muscle was slightly more involved than the gracilis
muscle. In the lower legs, the soleus and the medial
gastrocnemius were the most frequently affected
muscles, and in the anterior compartment the tibialis
anterior muscle was the most frequently affected.
Differences among these three MFM subforms were
much more subtle, but detectable on statistical analysis.
This revealed highly sensitive and speciﬁc criteria
(Fig. 5) that may be very useful for the detection of
individual MFM forms.
Other muscular dystrophies
Diagnosis of common muscular dystrophies such as
myotonic dystrophy type 1, facio-scapulo-humeral mus-
cular dystrophy and oculopharyngeal muscular dys-
trophy is usually based on classical clinical ﬁndings.
Therefore, in these muscular dystrophies the role of
muscle imaging has yet to be deﬁned. Recent studies
performed on these myopathies suggested that some
characteristic ﬁndings are present, even if there is less
diagnostic value compared with CM, LGMD and MFM
(Fig. 6).
Myotonic dystrophy
Myotonic dystrophy types 1 and 2 (DM1, DM2) are auto-
somal dominantly inherited multisystem disorders and
genetically characterised by pathogenic repeat mutations.
DM1 is—with an estimated prevalence of 1 in 8,000—the
second most common muscular dystrophy worldwide [52].
The clinical phenotype and pattern of muscle afﬂiction
differ between DM1 and DM2 (or proximal myotonic
myopathy = PROMM) but also show some overlap. Almost
all DM1 patients show signs of fatty degeneration and/or
oedematous changes in the striated muscles on muscular
MRI. Most of the patients show severe fatty degeneration of
the proximal and distal lower limb muscles. There is a
predominant afﬂiction of the anterior compartment of the
thighs compared with the posterior compartment with a
relative sparing of the rectus femoris muscles [27, 53, 54].
Particularly, the vastus muscles frequently show a semi-
lunar peri-femoral area of fatty degeneration [53, 55]. In the
lower legs of DM1 patients, the gastrocnemius muscles
show early and frequent involvement, whereas the posterior
tibial muscles are relatively unaffected. In addition, whole-
body MRI protocols can frequently detect the involvement
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of other organs in DM1 patients. Dypshagia is a common
clinical ﬁnding in DM1 patients, which is reﬂected by a
substantial dilatation of the oesophagus that can be easily
detected and rated on MRI (Fig. 2).
Contrary to DM1, patients with DM2 are less affected
based on MRI ﬁndings. A recently published whole-body
MRI study including DM1 and DM2 patients showed that
most of the DM2 patients showed no fatty degeneration,
Fig. 5 Muscle imaging differences in myoﬁbrillar myopathies.
Highly speciﬁc and sensitive statistical criteria were identiﬁed
in a systematic retrospective muscle imaging assessment in a
large series of 43 MFM patients [24]. Equal or greater afﬂiction
of the semitendinosus than the biceps femoris and equal or
greater afﬂiction of the peroneal group than the tibial anterior
muscles is highly speciﬁc for primary desminopathy and
crystallinopathy (18 out of 19 patients). Those of the remaining
patients who had equal or greater involvement of the sartorius than
the semi-tendinosus and equal or greater involvement of the adductor
magnus than the gracilis usually had a myotilin mutation (eight out
of nine patients). All eight patients who did not fulﬁl the criteria for
desmin and myotilin mutations and who had more involvement of
the medial than the lateral gastrocnemius showed a ﬁlamin C
mutation. Two of the three remaining patients had a ZASP and the
third a myotilin mutation
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and none of the patients showed any inﬂammatory
changes. The affected patients were exclusively men and
showed damage predominantly of the trunk muscles (such
as the erector spinae and gluteus) and in some cases
involvement of the proximal and lower leg muscles with
sparing of the rectus femoris and gracilis muscles in all
DM2 patients [27].
Facio-scapulo-humeral muscular dystrophy
Facio-scapulo-humeral muscular dystrophy (FSHD) is the
third most common muscular dystrophy (worldwide
prevalence 1:20,000) [52]. FSHD is characterised by
asymmetric loss of strength and atrophy of muscular tissue
starting in the face and shoulder region [56]. These typical
clinical ﬁndings are also mirrored on muscle imaging,
which shows marked asymmetry and involvement of the
medial gastrocnemius, the tibial anterior and the soleus
muscles in the lower legs. At the thigh, the most frequently
involved muscles are the semimembranosus, followed by
the biceps femoris, the semitendinosus muscle and the
adductor group muscles [57, 58].
Oculopharyngeal muscular dystrophy
Oculopharyngeal muscular dystrophy (OPMD) is a late-
onset autosomal dominant dystrophy, and is clinically
characterised by slowly progressive ptosis, dysphagia and
dysphonia. Proximal limb weakness often develops sub-
sequently [59]. There are few reports on muscle imaging
in OPMD. Abnormal fatty inﬁltration of the tongue,
masseter, neck, shoulder girdle, lumbar paraspinous and
the gluteus muscles have been described [60].
Muscle imaging in non-dystrophic myopathies
In contrast to muscular dystrophies, the weakness in
congenital myopathies (CM) is usually not progressive
Fig. 6 MuscleMRI of lower extremities in othermuscular dystrophies.
Myotonic dystrophy type I (a) is typically characterised by distal
more than proximal muscle involvement showing predominant
afﬂiction of the soleus, medial gastrocnemius and proximally the
anterior thigh compartment with relative sparing of the rectus
femoris. Patients with myotonic dystrophy type II (or proximal
myotonic myopathy = PROMM) (b) are often less affected and
show no fatty degeneration. Affected patients show more
involvement of the proximal muscles with afﬂiction of the
quadriceps and sparing of the rectus femoris and gracilis muscles.
FSHD (c) patients are often characterised by marked asymmetry
with the adductor magnus, hamstrings, rectus femoris and tibial
anterior being the most frequently affected muscles. OPMD (d)
patients show predominantly posterior thigh (adductor magnus,
semimembranosus and biceps femoris muscles) and posterior lower
leg (soleus) muscle involvement
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over time. Presentation of hypotonia and weakness is
“congenital” at birth or in the ﬁrst years of life with
delayed motor milestones. CMs are classiﬁed according to
the predominant structural abnormality in skeletal muscle.
In contrast to CM, most other non-progressive hereditary
myopathies present with intermittent, episodic muscular
symptoms as weakness (as episodic weakness in channe-
lopathies) or exercise-related muscle pain and fatigue (as
in metabolic myopathies related to disturbances of
glucose, fat or mitochondrial metabolism.)
Congenital myopathies
CMs show distinctive morphological abnormalities such
as rods, an abnormal number of central nuclei or (central
or multiple) cores. Often these ﬁndings guide the
physician to the correct genetic diagnosis. However, some
pathological overlap between genetically distinct disorders
has been described, making a genetic diagnosis sometimes
difﬁcult. Recently, different muscle imaging patterns in
CM have been identiﬁed, which can be of help in the
differential diagnosis.
Muscle imaging in patients with central core disease
(CCD) caused by mutations in the ryanodine receptor 1
gene (RYR1) shows a characteristic pattern with main
involvement of the gluteus maximus in the pelvis. At the
thigh level, the most severe changes are observed in the
medial compartment (adductor magnus) and in the
anterior compartment muscles (vastus lateralis, vastus
intermedius). Sparing of the adductor longus, gracilis and
biceps femoris muscles is common. In the distal lower
leg muscles, the soleus and the lateral head of the
gastrocnemius muscles are most severely involved [61,
62]. This pattern seems to be highly characteristic, as
muscular involvement in other congenital myopathies
caused by mutations in the SEPN1, ACTA1, NEB or
collagen VI encoding (COL6A1, COL6A2 and
COL6A3) genes is different [1]. In addition to RYR1,
patients with Ullrich CMD or Bethlem myopathy related to
collagen VI encoding genes also present with dominant
afﬂiction of the anterior thigh compartment. These patients
show an early and selective involvement of the centre of
the rectus femoris and vastus lateralis muscles. In addition,
in the lower legs there is often a rim of degenerative
changes between the soleus and the gastrocnemius muscle,
a pattern not observed in other CMs [63, 64].
Contrary to RYR1- and collagen 6A-related disorders,
which have marked afﬂiction of the anterior thigh, in most
other CM forms the posterior rather than anterior thigh
compartment muscles are affected. SEPN1 patients, often
presenting as a rigid spine (multi-minicore) myopathy,
typically show a selective afﬂiction of the sartorius and
posterior compartment muscles and a relative sparing of
the quadriceps and the gracilis muscle [25]. In patients
with dynamin 2-related autosomal dominant centronuclear
myopathy (DNM2-CNM), muscle imaging shows pre-
dominantly distal lower leg muscle afﬂiction (medial head
of the gastrocnemius, soleus), milder involvement of the
posterior thigh compartment (mostly the biceps femoris
and semimembranosus muscles) and the gluteus minimus
muscle. The sartorius and gracilis are often spared [65].
Congenital (nemaline) myopathies related to ACTA1 gene
mutations show predominantly distal anterior lower leg
and mild diffuse thigh compartment involvement. On the
other hand, nebulin gene-associated nemaline myopathies
often spare the thigh muscles and show selective distal
involvement of the soleus and tibial anterior muscles [66].
A useful ﬂowchart for the differential diagnosis of CM
using muscle imaging is provided in Fig. 7.
Muscle channelopathies and metabolic myopathies
Compared to the increasing data regarding the diagnostic
value of neuromuscular MRI in patients presenting with
dystrophic myopathies or non-dystrophic congenital myo-
pathies, data concerning MRI ﬁndings in muscle channe-
lopathies or metabolic myopathies are rather limited. A
recently published study focussed on patients with
myotonia congenital type Becker, a non-dystrophic gen-
eralised myotonia caused by mutations in the muscle
chloride gene. Although all patients presented with a
severe disabling myotonia, no fatty degeneration or
muscle oedema could be detected by using a whole-body
high-ﬁeld MRI protocol [67]. These ﬁndings suggest that
conventional MRI techniques are less sensitive in the
detection of changes in channelopathies. Recent exper-
imental studies using 23Na-MRI instead of or in combi-
nation with 1H-MRI have shed some light on the muscle
cell function and disease process in Na-channelopathies
by demonstrating Na-accumulation during episodes of
weakness [33, 68].
Future perspectives
During the past 5 years an abundant amount of data has
been published concerning the degree and pattern of
striated muscle involvement in inherited muscle disease.
These data have led to a new era in the non-invasive
diagnosis of neuromuscular diseases. The diagnostic
ﬂowcharts presented in this review are based on these
data collected during the past few years. However, this is
just a beginning, and we have still a long way to go.
Continuously new genetic disease entities leading to
muscle dystrophy can be identiﬁed and described by
using new diagnostic tools. Therefore, the role of neuro-
muscular imaging has to be considered as a dynamic ﬁeld
of research that will gain even more importance in the
near future. While the ﬁrst imaging approaches focussed
mainly on certain muscle groups primarily of the lower
limbs, current and future imaging protocols should
consider a “whole-body approach” such as whole-body
muscle MRI including the muscle of the trunk, shoulder
girdles and upper extremities. This can extend the
possibilities for pattern description and recognition.
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In addition to the available cross-sectional data, it
would be interesting to gain more longitudinal data in
order to understand the disease evolution and the
prognostic role of subclinical changes detected by MRI
or ultrasound. In particular, the possible role of imaging
for treatment monitoring is of great interest, and ﬁrst
approaches in metabolic diseases are promising [69, 70].
The potential role of advanced MRI techniques such as
perfusion-weighted imaging, diffusion-weighted imaging
and MR spectroscopy is currently unknown. It can be
suggested that some of these techniques can further
increase the sensitivity in the detection of subtle changes
in the striated muscle and contribute to a better under-
standing of the underlying pathophysiological mechanism
[32–35]. It is of great interest whether these imaging
techniques will show additional diagnostic and prognostic
value. High-ﬁeld MRI is increasingly being used in the
clinical setting [71, 72]. Due to a substantial increase in the
signal-to-noise ratio, in vivo imaging at higher magnetic
ﬁeld allows faster image acquisition and higher spatial
resolutions. The ﬁrst whole-body high-ﬁeld muscle MRI
protocols have been recently described [27, 51, 67]. Future
studies have to investigate whether structural and quantita-
tive (perfusion MRI, MR spectroscopy) high-ﬁeld MRI
protocols do have added value in the diagnosis of
hereditary, metabolic or inﬂammatory muscle disease.
The role of contrast-enhanced imaging US and MRI
techniques is still unclear. The ﬁrst imaging studies using
gadolinium(Gd)-based contrast-enhanced MRI have been
published in denervated muscles and inherited dystrophic
Fig. 7 Flowchart showing a useful approach to the differential
diagnosis of congenital myopathies. We highly recommend
systematically analysing muscle imaging ﬁndings beginning with the
thigh muscles. The ﬁrst distinction should be made according to the
relation of posterior to anterior thigh muscle involvement. Most CMs
show greater afﬂiction of the posterior rather than the anterior thigh
muscles. In the second step, the same relation should be assessed in the
lower legs. Predominant posterior thigh and posterior lower leg
involvement with sparing of the gracilis and sartorius but marked
afﬂiction of the soleus and medial gastrocnemius is observed in DNM2-
CNM. Predominantly posterior thigh with marked afﬂiction of the
sartorius and predominantly diffuse posterior lower leg involvement are
typical ﬁndings of SEPN1-related CM. Posterior thigh but anterior leg
involvement was observed in CM patients with ACTA1 mutations. On
the other hand, marked anterior thigh afﬂiction is seen in RYR1- and
collagen 6A-related CM. In addition, RYR1 patients show sparing of the
rectus femoris, gracilis and biceps femoris and often marked afﬂiction of
the soleus muscle, while patients with a collagen 6A defect show a
special rim with the beginning of degeneration within the rectus femoris
muscle and a degenerative rim between the soleus und gastrocnemius
muscles. Typical muscle imaging ﬁndings of patients with proven
mutations in the DNM2, SEPN1, ACTA1, RYR1 and collagen 6A1 are
provided
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muscle disease [31, 73]. However, whether Gd-based
contrast MRI leads to be an improvement in the diagnosis
of hereditary muscle dystrophies is not clear. Perhaps
more speciﬁc contrast media agents such as small iron
oxide particles (SPIO) can contribute to a better visual-
isation and understanding of inﬂammatory and degener-
ative changes in striated muscles.
Conclusion
The importance of clinical muscular imaging is becoming
increasingly obvious in patients with suspected or proven
inherited muscle diseases. Musculoskeletal US is a well-
established, easily applicable and cost-effective screening
technique for the detection of dystrophic changes in the
striated muscle, particularly in young children. However,
MRI is becoming the technique of choice in the diagnostic
workup of patients with suspected hereditary muscle
diseases. The role of MRI goes far beyond the pure
detection of inﬂammatory and/or dystrophic changes.
Using whole-body MRI protocols, we are able to identify
muscle involvement per muscle and quantify the degree of
dystrophic changes according to established rating scales
leading to a description of involvement patterns. These
sometimes distinct patterns of involvement can further
narrow the differential diagnosis and might lead to the
correct diagnosis even before invasive diagnostic proce-
dures such as muscle biopsy.
Recently introduced advanced and quantitative MRI
methods including T2 relaxation time measurements,
muscle fat quantiﬁcation using the 3-point Dixon technique,
magnetic resonance spectroscopy and perfusion imaging are
quite promising, but also challenging in terms of the
quantiﬁcation and further speciﬁcation of the disease process
and disease monitoring. In addition, quantiﬁcation of muscle
volume by muscle MRI and advanced quantitative MRI
methods may be used for controlling the safety and efﬁcacy
of (experimental) treatment. Further in vivo studies are
needed to investigate whether these methods are useful for
implementation in a clinical routine setting.
Acknowledgments The authors wish to thank Dr. Cornelia
Kornblum for her helpful comments and Jennifer Bradshaw for
the critical reading of the manuscript. D.F. was supported by the
Deutsche Forschungsgemeinschaft (DFG) and is a member of the
German Network on Muscular Dystrophies (MD-NET) funded by
the German Ministry of Education and Research (BMBF, Bonn,
Germany).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
References
1. Mercuri E, Jungbluth H, Muntoni F
(2005) Muscle imaging in clinical
practice: diagnostic value of muscle
magnetic resonance imaging in
inherited neuromuscular disorders. Curr
Opin Neurol 18:526–537
2. Mercuri E, Pichiecchio A, Allsop J,
Messina S, Pane M, Muntoni F (2007)
Muscle MRI in inherited neuromuscular
disorders: past, present and future. J
Magn Reson Imaging 25:433–440
3. Peters SA, Köhler C, Schara U et al
(2008) Muscular magnetic resonance
imaging for evaluation of myopathies
on children. Klin Pädiatr 220:37–46
4. Klotzenburg M, Yousry T (2007)
Magnetic resonance imaging of skeletal
muscle. Curr Opin Neurol 20:595–599
5. Fleckenstein JL, Crues JV III, Reimers
CD (1996) Muscle imaging in health
and disease. Springer, New York
6. Arts IM, Pillen S, Overeem S, Jurgen
SH, Zwarts MJ (2007) Rise and fall of
skeletal muscle size over the entire life
span. J Am Geriatr Soc 55:1150–1152
7. Kanehisa H, Ikegawa S, Tsunoda N,
Fukunaga T (1994) Cross-sectional
areas of fat and muscle in limbs during
growth and middle age. In J Sports Med
15:420–425
8. Brown M (2008) Skeletal muscle and
bone: effect of sex steroids and ageing.
Adv Physiol Educ 32:10–126
9. Doherty TJ (2003) Invited review:
ageing and sacropenia. J Appl Physiol
95:717–727
10. Pillen S, Arts IM, Zwarts MJ (2008)
Muscle ultrasound in neuromuscular
disorders. Muscle Nerve 37:679–693
11. Chi-Fishman G, Hicks JE, Cintas HM,
Sonnies BC, Gerber LH (2004)
Ultrasound imaging distinguishes
between normal and weak muscles.
Arch Phys Med Rehabil 85:980–986
12. Scheel AK, Reimers CD (2004)
Detection of fasciculations and other
types of muscular hyperkinesias with
ultrasound. Ultraschall Med 25:337–
341
13. Pillen S, Nienhuis M, van Dijk JP, Arts
IM, van Alfen N, Zwarts MJ (2009)
Muscles alive: ultrasound detects
ﬁbrillations. Clin Neurophysiol
120:932–936
14. Pillen S, Keimpema M, Bievelstein
RAJ, Verrips A, Kruijsbergen-Raijmann
W, Zwarts MJ (2006) Skeletal muscle
ultrasonography: visual versus
quantitative evaluation. Ultrasound Med
Biol 32:1315–1321
15. Heckmatt JZ, Leeman S, Dubowitz V
(1982) Ultrasound imaging in the
diagnosis of muscle disease. J Pediatr
101:656–660
16. Pillen S, Scholten RR, Zwarts MJ,
Verrips A (2003) Quantitative skeletal
muscle ultrasonography in children with
suspected neuromuscular disease.
Muscle Nerve 27:142–147
17. Pohle R, Fischer D, von Rohden L
(2000) Computer-supported tissue
characterization in musculoskeletal
ultrasonography. Ultraschall Med
21:245–252
18. Pillen S, van Dijk JP, Weijers G,
Raijmann W, de Korte CL, Zwarts MJ
(2009) Quantitative gray-scale analysis
in skeletal muscle ultrasound: a
comparison study of two ultrasound
devices. Muscle Nerve 39:781–786
19. Pillen S, Verrips A, van Alfen N, Arts
IM, Sie LT, Zwarts MJ (2007)
Quantitative skeletal muscle ultrasound:
diagnostic value in childhood
neuromuscular disease. Neuromuscul
Disord 17:509–516
20. Pillen S, Morava E, van Keimpema M,
ter Laak HJ, de Vries MC, Rodenburg
RJ (2006) Skeletal muscle
ultrasonography in children with
dysfunction in the oxidative
phosphorylation system.
Neuropediatrics 37:142–147
2458
21. O’Sullivan PJ, Gorman GM, Hardiman
OM, Farrel MJ, Logan PM (2006)
Sonographically guided percutaneous
muscle biopsy in diagnosis of
neuromuscular disease: a useful
alternative to open surgical biopsy. J
Ultrasound Med 25:1–6
22. Ozsarlak O, Schepens E, Parizel PM et
al (2001) Hereditary neuromuscular
diseases. Eur J Radiol 40:184–197
23. Schedel H, Reimers CD, Nägele M,
Witt TN, Pongratz DE, Vogl T (1992)
Imaging techniques in myotonic
dystrophy: a comparative study of
ultrasound, computed tomography and
magnetic resonance imaging of skeletal
muscles. Eur J Radiol 15:230–238
24. Alanen AM, Falck B, Kalimo H, Komu
ME, Sonninen VH (1994) Ultrasound,
computed tomography and magnetic
resonance imaging in myopathies:
correlation with electromyography and
histopathology. Acta Neurol Scand
89:336–346
25. Mercuri E, Talim B, Moghadaszadeh B
et al (2002) Clinical and imaging
ﬁndings in six cases of congenital
muscular dystrophy with rigid spine
syndrome linked to chromosome 1p
(RSMD1). Neuromuscul Disord
12:631–638
26. Fischer D, Kley RA, Strach K et al
(2008) Distinct muscle imaging patterns
in myoﬁbrillar myopathies. Neurology
71:758–765
27. Kornblum C, Lutterbey G, BogdanowM,
Kesper K, Schild H, Schröder R, Wattjes
MP (2006) Distinct neuromuscular
phenotypes in myotonic dystrophy types
1 and 2. Awhole body highﬁeld MRI
study. J Neurol 253:753–761
28. Modolell I, Mearin F, Baudet JS, Gámez
J, Cervera C, Malagelada JR (1999)
Pharyngo-esophageal disturbances in
patients with myotonic dystrophy. Scand
J Gastroenterol 34:878–882
29. Strach K, Sommer T, Grohé C et al
(2008) Clinical, genetic and cardiac
magnetic resonance ﬁndings in primary
desminopathies. Neuromuscul Disord
18:475–482
30. Straub V, Donahue KM, Allamand V,
Davisson RL, Kim YR, Campbell KP
(2000) Contrast agent-enhanced
magnetic resonance imaging of skeletal
muscle damage in animal models of
muscular dystrophy. Magn Reson Med
44:655–659
31. Schmidt S, Vieweger A, Obst M et al
(2009) Dysferlin-deﬁcient muscular
dystrophy: gadﬂuorine M suitability at
MR imaging in a mouse model.
Radiology 250:87–94
32. Heemskerk AM, Strijkers GJ, Vilanova
A, Drost MR, Nicolay K (2005)
Determination of mouse skeletal muscle
architecture using three-dimensional
diffusion tensor imaging. Magn Reson
Med 53:1333–1340
33. Weber MA, Nielles-Vallespin S, Essig
M, Jurkat-Rott K, Kauczor HU,
Lehmann-Horn F (2006) Muscle Na+
channelopathies: MRI detects
intracellular 23Na accumulation during
episodic weakness. Neurology
67:1151–1158
34. Hsieh TJ, Wang CK, Hy C, Jong YJ, Li
CW, Liu GC (2007) In vivo proton
magnetic resonance spectroscopy
assessment for muscle metabolism in
neuromuscular disorders. J Pediatr
151:319–321
35. Weber MA, Krix M, Delorme S (2007)
Quantitative evaluation of muscle
perfusion with CEUS and with MRI.
Eur Radiol 17:2663–2674
36. Guglieri M, Straub V, Bushby K,
Lochmüller H (2008) Limb-girdle
muscular dystrophies. Curr Opin Neurol
21:576–584
37. Bonnemann CG, Finkel RS (2002)
Sarcolemmal proteins and the spectrum
of limb-girdle muscular dystrophies.
Semin Pediatr Neurol 9:81–99
38. Mercuri E, Brockington M, Straub V et
al (2003) Phenotypic spectrum
associated with mutations in the
fukutin-related protein gene. Ann
Neurol 53:537–542
39. Poppe M, Cree L, Bourke J et al (2003)
The phenotype of limb-girdle muscular
dystrophy type 2I. Neurology 60:1246–
1251
40. Fischer D, Walter MC, Kepser K et al
(2005) Diagnostic value of muscle MRI
in differentiating LGMD2I from other
LGMDs. J Neurol 252:538–547
41. Mercuri E, Bushby K, Ricci E et al
(2005) Muscle MRI ﬁndings in patients
with limb girdle muscular dystrophy
with calpain 3 deﬁciency (LGMD2A)
and early contractures. Neuromuscul
Disord 15:164–171
42. Liu J, Aoki M, Illa I et al (1998)
Dysferlin, a novel skeletal muscle gene,
is mutated in Myoshi myopathy and
limb girdle muscular dystrophy. Nat
Genet 20:31–36
43. Illa I, Serrano-Munuera C, Gallardo E et
al (2001) Distal anterior compartment
myopathy: a dysferlin mutation causing
a new muscular dystrophy phenotype.
Ann Neurol 49:130–134
44. Illa I, De Luna N, Dominguez-Perles
R et al (2007) Symptomatic dysferlin
gene mutation carriers:
characterization of two cases.
Neurology 68:1284–1289
45. Cupler EJ, Bohlega S, Hessler R,
McLean D, Stigsby B, Ahmad J (1998)
Miyoshi myopathy in Saudi Arabia:
clinical, electrophysiological,
histopathological and radiological
features. Neuromuscul Disord 8:321–
326
46. Kesper K, Kornblum C, Reimann J,
Lutterbey G, Schröder R, Wattjes MP
(2009) Pattern of skeletal muscle
involvement in primary
dysferlinopathies: a whole-body 3.0-T
magnetic resonance imaging study. Acta
Neurol Scand 120:111–118
47. Eymard B, Romero NB, Leturcq F et al
(1997) Primary adhalinopathy (alpha-
sarcoglycanopathy): clinical,
pathologic, and genetic correlation in 20
patients with autosomal recessive
muscular dystrophy. Neurology
48:1227–1234
48. Lamminen AE (1990) Magnetic
resonance imaging of primary skeletal
muscle diseases: patterns of distribution
and severity of involvement. Br J
Radiol 63:946–950
49. Liu GC, Jong YJ, Chiang C, Jaw TS
(1993) Duchenne muscular dystrophy:
MR grading system with functional
correlation. Radiology 186:475–480
50. Lodi R, Muntoni F, Taylor J et al (1997)
Correlative MR imaging and 31P-MR
spectroscopy study in sarcoglycan
deﬁcient limb girdle muscular
dystrophy. Neuromuscul Disord 7:505–
511
51. Selcen D (2008) Myoﬁbrillar
myopathies. Curr Opin Neurol 21:585–
589
52. Emery AE (1991) Population
frequencies of inherited neuromuscular
diseases—a world survey. Neuromuscul
Disord 1:19–29
53. Castillo L, Pumar JM, Rodriguez JR et
al (1993) Magnetic-resonance-imaging
of muscles in myotonic dystrophy. Eur J
Radiol 17:141–144
54. Damian MS, Bachmann G, Herrmann
D, Dorndorf W (1993) Magnetic
resonance imaging of muscle and brain
in myotonic dystrophy. J Neurol 240:8–
12
55. Serratrice G, Salamon G, Jiddane M,
Gastaut JL, Pellissier JF, Pouget J
(1985) Results of muscular x-ray
computed tomography in 145 cases of
neuromuscular disease. Rev Neurol
(Paris) 141:404–412
56. Tawil R, Van Der Maarel SM (2006)
Facioscapulohumeral muscular
dystrophy. Muscle Nerve 34:1–15
57. Olsen DB, Gideon P, Jeppesen TD,
Vissing J (2006) Leg muscle
involvement in facioscapulohumeral
muscular dystrophy assessed by MRI. J
Neurol 253:1437–1441
58. Kan HE, Scheenen TWJ, Wohlgemuth
M et al (2009) Quantitative MR
imaging of individual muscle
involvement in facioscapulohumeral
muscular dystrophy. Neuromuscul
Disord 19:357–362
59. Brais B, Rouleau GA, Bouchard JP,
Fardeau M, Tomé FMS (1999)
Oculopharyngeal muscular dystrophy.
Semin Neurol 19:59–66
60. King MK, Lee RR, Davis LE (2005)
Magnetic resonance imaging and
computed tomography of skeletal
muscles in oculopharyngeal muscular
dystrophy. J Clin Neuromuscul Dis
6:103–108
2459
61. Fischer D, Herasse M, Ferreiro A et al
(2006) Muscle imaging in dominant
core myopathies linked or unlinked to
the ryanodine receptor 1 gene.
Neurology 67:2217–2220
62. Jungbluth H, Davis MR, Muller C et al
(2004) Magnetic resonance imaging of
muscle in congenital myopathies
associated with RYR1 mutations.
Neuromuscul Disord 14:785–790
63. Mercuri E, Lampe A, Allsop J et al
(2005) Muscle MRI in Ullrich
congenital muscular dystrophy and
Bethlem myopathy. Neuromuscul
Disord 15:303–310
64. Mercuri E, Cini C, Pichiecchio A et al
(2003) Muscle magnetic resonance
imaging in patients with congenital
muscular dystrophy and Ullrich
phenotype. Neuromuscul Disord
13:554–558
65. Fischer D, Herasse M, Bitoun M et al
(2006) Characterization of the muscle
involvement in dynamin 2-related
centronuclear myopathy. Brain
129:1463–1469
66. Jungbluth H, Sewry CA, Counsell S
et al (2004) Magnetic resonance
imaging of muscle in nemaline
myopathy. Neuromuscul Disord
14:779–784
67. Kornblum C, Lutterbey GG, Czermin
B, Reimann J, von Kleist-Retzow JC,
Jurkat-Rott K, Wattjes MP (2010)
Whole-body high-ﬁeld MRI shows no
skeletal muscle degeneration in young
patients with recessive myotonia
congenita. Acta Neurol Scand 121:131–
135
68. Weber MA, Niellies-Vallespin S,
Huttner HB et al (2006) Evaluation
of patients with paramyotonica at
23Na MR imaging during cold-
induced weakness. Radiology
240:489–500
69. Pichiecchio A, Poloni GU, Ravaglia S
et al (2009) Enzyme replacement
therapy in adult- onset glycogenosis II.
Is quantitative muscle MRI helpful?
Muscle Nerve 40:122–125
70. Kornblum C, Schröder R, Müller K et al
(2005) Creatine has no beneﬁcial effect
on skeletal muscle energy metabolism
in patients with single mitochondrial
DNA deletions: a placebo-controlled
double blind 31P-MRS crossover study.
Eur J Neurol 12:300–309
71. Wattjes MP, Barkhof F (2009) High
ﬁeld MRI in the diagnosis of multiple
sclerosis: high ﬁeld-high yield?
Neuroradiology 51:279–292
72. Willinek WA, Schild HH (2008)
Clinical advantages of 3.0T MRI over
1.5T. Eur J Radiol 65:2–14
73. Bendzus M, Koltzenburg M (2001)
Visualization of denervated muscle by
gadolinium-enhanced MRI. Neurology
57:1709–1711
2460
